Everything discussed elsewhere on this site is framed around research use. If you compete under WADA, NCAA, or a similar testing body, that framing does not protect you — anti-doping rules operate on an entirely separate and much stricter standard than FDA compounding status. This is a dedicated look at that distinction.
WADA Doesn’t Care About FDA Category Status
A peptide coming off the FDA’s Category 2 list, or even being added to the 503A bulks list after a favorable PCAC vote, has zero bearing on whether that substance is prohibited under the WADA Code. Growth hormone secretagogues, IGF-1 and its analogs, and several peptides discussed throughout this site fall under WADA’s S2 (peptide hormones, growth factors) category and are prohibited at all times, in and out of competition, for athletes subject to testing.
Which Categories of Peptides Are Typically Prohibited
Growth hormone releasing peptides (CJC-1295, Ipamorelin, GHRP-2 and similar), IGF-1 and IGF-1 LR3, and any substance with growth-factor or GH-mimetic activity are generally captured under WADA’s prohibited list. This is a broad category, and specific compound status can and does change year to year — the current WADA Prohibited List should always be checked directly rather than assumed from general peptide knowledge.
The Detection Window Problem
Detection methods for peptide hormones have improved significantly, and many now carry meaningfully longer detection windows than athletes assume based on older information. “It clears fast” assumptions from years ago are not a reliable basis for a testing-era decision.
If You’re Not Currently Tested But Might Be Later
Collegiate athletes moving to professional or Olympic-pathway competition, and amateur athletes considering a jump to a tested federation, should assume any research-use peptide history is a relevant disclosure question for whatever governing body they’re entering — not something that simply resolves itself by stopping beforehand.